Todd is the Associate Vice President of Research and Executive Director for the office. He leads the team who focus on creating value from intellectual property developed by Emory researchers. Todd has worked extensively with researchers to translate their promising scientific and medical discoveries into new products that benefit society. This crucial activity helps assure that research is translated into practical applications, including new life-saving medical products that benefit the public who helped to fund it.

Chris Sloan is the co-chair of the Firm’s Emerging Companies and Venture Capital Group, focusing on corporate structure and governance, venture capital financings, M&A, contract law, and IP protection for early-stage, high-growth businesses. He advises technology and healthcare companies on complex IT transactions and emerging technologies like AI, digital health, and blockchain.

Dr. Charleson S. Bell, PhD is a modern day polymath, pioneering and drawing from multiple fields and bodies of knowledge to solve many of the world's current problems. A multi-talented man of Faith, Dr. Bell not only excels in Innovation and Research but also the arts including Creative Writing and Music/Film Production. Unifying and uplifting others, either through innovation or art, is his passion.

David Blittner is chair of the private equity transactions group and a partner in the New York office. David is a seasoned corporate transactions attorney with over 30 years of experience practicing in New York. He advises private equity sponsors in connection with acquisitions, dispositions and financings. He has deep experience steering leveraged buyouts and dispositions of public and private companies, as well as minority investments, public recapitalizations and restructurings.

As founder and CEO of ZIRUS, David oversaw the development of a host based antiviral drug platforms. David was the Head of the Biotechnology Patent Group at Needle & Rosenberg as the group rose to national prominence through its association with the NIH, NIAID, and the CDC. He was also a co-founder of Georgia Venture Partners and a co-founder and member of the Board of Directors at Maxia Pharmaceuticals, where he directed the strategy of the drug patent portfolio before it was acquired by Incyte Pharmaceuticals.

Rebecca Silberman is an Investment Director on the Venture Team at RA Capital Management. Rebecca's primary responsibilities include identifying compelling opportunities for new company creation and investments in early-stage companies, as well as advising RA's portfolio companies. Rebecca has a BA in Biology from Colgate University and a PhD in Biology from MIT.

An internationally renowned political scientist, management scholar and visionary leader, Diermeier is Vanderbilt’s ninth chancellor.

Vanderbilt named Diermeier chancellor in late 2019 after an extensive search by the Board of Trust. In May 2024, the Board of Trust extended Diermeier’s contract until 2035 “as a demonstration of our confidence in Chancellor Diermeier’s leadership and to support the realization of his long-term vision for the university.